Mohamed Khobreh

Managing Partner

Mohamed Khobreh is a co-founder and managing partner of NG Bio, a United Kingdom firm that describes itself as an early-stage investor and venture builder in immunology, backing and creating companies that treat disease through the immune system, with autoimmunity and women's health among its areas; its dedicated initiative xxplore by NG Bio builds women's health companies, and its portfolio has included Cellesce, acquired by Danaher. He leads the fund's investment strategy and works with its limited partners and co-investors on their holdings. Before founding NG Bio he built and led the life sciences investment strategy of a family office, where the firm reports a track record of more than three and a half times returns over six years. He is a partner and investment committee member at One Rosemond, sits on the board of the biotechnology company Bastion Therapeutics, and is an investor in the British companies LightOx and Abselion. He holds a master's degree in risk management from Bayes Business School and studied corporate law and governance at the London School of Economics and Political Science.